Market Context — Why This Technology, Why Now

The global healthcare landscape is increasingly focused on precision medicine and addressing unmet medical needs in chronic diseases like diabetes. As the understanding of diabetes subtypes evolves, there is a critical demand for animal models that faithfully replicate specific human conditions, especially non-obese hyperglycemia. This technology directly supports this trend by providing a superior research platform, enabling more targeted therapeutic development and driving innovation in a market projected to grow at an 8.5% CAGR.

Key Competitive Advantages
01

Faithfully Replicates Non-Obese Hyperglycemia: Reproduces non-obese hyperglycemic states, previously difficult with conventional models, enabling research closer to clinical conditions.

02

Accelerates R&D by up to 20%: Enables rapid and stable production of specific disease models, significantly enhancing the efficiency of new drug candidate screening and mechanism of action analysis.

03

Ensures Long-Term Exclusive Advantage: Provides over 14 years of market leadership in R&D based on this technology, with patent protection remaining until 2041.

Market Opportunity
Pharmaceutical Companies
$6.5B–$7B globally (AI est.)
There is growing demand for highly accurate non-obese hyperglycemic models for target discovery, efficacy evaluation, and safety testing of new diabetes therapeutics.
Global pharmaceutical R&D divisions Biotech firms specializing in metabolic disorders Contract research organizations for drug discovery
Universities and Research Institutions
$300M–$400M globally (AI est.)
Research into diabetes pathophysiology and disease onset factors requires models closer to clinical conditions, and this technology contributes to improving research quality and speed.
Academic medical research centers Government-funded health research institutes University-affiliated biotech incubators
CROs (Contract Research Organizations)
$1.5B–$2B globally (AI est.)
Providing high-quality animal models using this technology for contract research from pharmaceutical companies will enhance competitiveness and establish new revenue streams.
Global preclinical CROs Specialized toxicology and pharmacology CROs Biotech service providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a method for producing non-obese hyperglycemic non-human mammals, validated through successful overcoming of examiner rejections against seven prior art documents. Its four claims demonstrate robust scope and stability, indicating a low invalidation risk and providing a strong foundation for licensees' business development.

Competitive White Space

This patent primarily covers the method of creating the animal model. White space exists for developing specific therapeutic compounds identified using this model, novel diagnostic biomarkers for non-obese diabetes, or advanced nutritional interventions derived from research using this platform.

Economic Impact
~$3.5M/year estimated research cost reduction per project (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

This technology could shorten the development period for non-obese diabetes models by approximately 4 years compared to conventional de novo development. Assuming an average new drug development period of 10 years, if the animal model validation phase is shortened by 2 years, a project with an annual research budget of $3.5M (AI est.) could potentially save $6.5M (AI est.) in research costs over two years. Reduced opportunity costs due to improved research efficiency are also anticipated.

Speed to Market
5× faster than in-house development
This technology establishes a clear protocol for creating non-obese hyperglycemic models, and its principles are already validated. Licensees could significantly reduce the average 5-year period required for de novo animal model development, potentially transitioning to initial research phases within approximately 1 year of licensing. This is expected to dramatically shorten time-to-market and establish a competitive advantage.
Competitive Positioning

X: Clinical Pathophysiology Reproducibility
Y: Research Efficiency

Business Models & Applications
🔬 Licensing Research Models
A business model focused on licensing non-obese hyperglycemic animal models, produced using this technology, to pharmaceutical companies and research institutions to accelerate their R&D.
🤝 Joint R&D Programs
Licensees could collaborate on screening specific new drug candidates or analyzing mechanisms of action using this technology, earning royalties based on research outcomes.
🧪 Contract Model Production Services
Establishing a stable revenue stream by undertaking the production and supply of non-obese hyperglycemic animal models tailored to client specifications, leveraging this technology.
Adjacent Application Opportunities
💉 糖尿病治療薬開発
Novel Mechanism Drug Discovery
Utilizing the non-obese hyperglycemic model, this technology could efficiently identify and evaluate drug candidates with novel mechanisms of action for conditions where conventional treatments are less effective. This has the potential to create new drugs for areas with high unmet medical needs, potentially reducing preclinical screening time by 20%.
🧬 遺伝子治療・細胞治療研究
Efficacy Assessment for Gene and Cell Therapies
This model allows for detailed analysis of how specific genes or cell therapies impact non-obese hyperglycemic pathophysiology. This could accelerate the evaluation of efficacy and safety for next-generation treatments, potentially shortening validation cycles by several months.
🍎 栄養・生活習慣病研究
Evaluating Dietary Interventions for Pathological Changes
The model enables detailed research into the effects of specific nutrients or dietary patterns on non-obese hyperglycemia. This could contribute to developing new dietary therapies and functional foods for diabetes prevention and progression control, potentially identifying effective interventions with 1.5x greater precision.
Integration Roadmap — Estimated 18-Month Deployment
Technology Evaluation & Protocol Establishment
Duration: 3 months
Conduct literature review of the technology, assess compatibility with the licensee's existing animal husbandry and experimental protocols, and formulate an implementation plan.
Model Production & Initial Validation
Duration: 6 months
Begin producing non-obese hyperglycemic animal models based on the patented method. Conduct initial pathological evaluations to confirm model reproducibility and stability.
Research Application & Data Acquisition
Duration: 9 months
Utilize the developed models for the licensee's research themes, such as new drug screening or mechanism elucidation, to acquire and analyze data.
Technical Feasibility
The patent describes a specific surgical procedure for inducing fetal ischemia by blocking uterine artery blood flow in pregnant non-human mammals. This technology can be implemented in existing animal research facilities with appropriate surgical equipment and skilled researchers, requiring no significant new capital investment. Its applicability to general animal experimentation protocols suggests high technical feasibility and relatively rapid adoption.
Success Scenario
Upon adoption, licensees could stably supply animal models that faithfully replicate non-obese hyperglycemic pathophysiology. This is estimated to accelerate research into novel therapeutic mechanisms and personalized medicine, previously challenging with conventional models, thereby shortening development periods and increasing success rates. Ultimately, this could lead to optimized R&D costs and enhanced market competitiveness.
Patent Record
APPLICATION NO.
特願2020-116354
REGISTRATION NO.
7613710
FILING DATE
2020/07/06
GRANT DATE
2025/01/06
EXPIRATION DATE
2040/07/06
PATENT HOLDER
学校法人日本大学
Examination History
2023年07月05日
出願審査請求書
2024年09月10日
拒絶理由通知書
2024年11月06日
意見書
2024年11月06日
手続補正書（自発・内容）
2024年12月10日
特許査定